ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,527.60
      0.34%
      US Tech 100
      19,604.40
      0.64%
      Dow Jones
      39,280.91
      -0.13%
      Brent Oil
      86.20
      -0.28%
      Bitcoin
      60,204.45
      -2.94%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. BioLineRx Ltd (BLRX)

      7. BioLineRx Ltd (BLRX) News

      BLRX

      BioLineRx (BLRX)

      BioLineRx Ltd
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:BLRX
      DateTimeSourceHeadlineSymbolCompany
      1:00PMiHub NewswireFeaturedFreedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent
      08/08/20235:25PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
      07/17/20237:10AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:BLRXBioLineRx Ltd
      06/23/20234:17PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
      05/24/20237:07AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
      04/25/20237:08AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
      04/17/202311:09AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
      03/22/20237:48AMEdgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:BLRXBioLineRx Ltd
      03/22/20237:33AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
      01/20/20234:32PMEdgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:BLRXBioLineRx Ltd
      01/04/20237:06AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
      12/20/20227:09AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
      11/15/202212:05PMTipRanksBioline RX Ltd Sponsored ADR (BLRX) Receives a Buy from H.C. WainwrightNASDAQ:BLRXBioLineRx Ltd
      11/15/20227:16AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
      11/10/20227:09AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
      11/04/20224:30PMPR Newswire (US)BioLineRx Announces Receipt of Nasdaq Minimum Bid Price NotificationNASDAQ:BLRXBioLineRx Ltd
      11/03/20229:21AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
      09/28/202212:15PMTipRanksBioline RX Ltd Sponsored ADR (BLRX) Gets a Buy from H.C. WainwrightNASDAQ:BLRXBioLineRx Ltd
      09/27/20227:01AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
      09/21/20228:01AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
      09/20/20224:31PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:BLRXBioLineRx Ltd
      09/19/202210:53AMTipRanksBioLineRx (NASDAQ:BLRX) Nosedives on $15M Direct OfferingNASDAQ:BLRXBioLineRx Ltd
      09/19/20228:08AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
      09/15/20228:40AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
      09/12/20228:17AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
      09/09/20224:16PMEdgar (US Regulatory)Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)NASDAQ:BLRXBioLineRx Ltd
      08/16/20227:20AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:BLRXBioLineRx Ltd
      06/30/20229:42AMPR Newswire (Canada)BioLineRx conclut une entente de codéveloppement avec GenFleet pour développer davantage le Motixafortide pour le traitement de l'adénocarcinome canalaire pancréatique, selon les conseils de MSQ VenturesNASDAQ:BLRXBioLineRx Ltd
      06/29/20228:00AMPR Newswire (Canada)BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ VenturesNASDAQ:BLRXBioLineRx Ltd
      06/29/20228:00AMPR Newswire (US)BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ VenturesNASDAQ:BLRXBioLineRx Ltd
       Showing the most relevant articles for your search:NASDAQ:BLRX